|
Patent landscape, scope, and claims: |
United States Patent 11,680,069: Scope of Claims, Crystal-Form Coverage, and US Patent Landscape
What is claimed in US 11,680,069?
US Patent 11,680,069 claims a specific crystalline freebase of a defined stereochemical and structural small molecule, plus form-dependent pharmaceutical compositions and simple formulation processes.
Core API identity (same scaffold across all claims)
All independent claim coverage centers on:
Crystalline freebase (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide
Key structural points embedded in the claim are:
- Freebase form (not a salt)
- Stereochemistry: (3S,4R)
- Substitution pattern: 3-ethyl, imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl at position 4
- Amide N-substituent: N-(2,2,2-trifluoroethyl)
Crystal-form dependent API claims
The patent then partitions protection by solid-state form of that same freebase:
| Claim Nos. |
Claim focus |
Crystal-form limitation |
| 1 |
API as crystalline freebase |
No hydrate/anhydrate/sovlate subtyping stated |
| 2 |
Claim 1 dependency |
Anhydrate |
| 3-4 |
Claim 1 dependency |
Hydrate, and dependent specifies hemihydrate |
| 5 |
Claim 1 dependency |
Solvate |
Composition claims (API + carrier)
The patent covers a pharmaceutical composition comprising that crystalline freebase, plus a pharmaceutically acceptable carrier, with sublimits for solid dosage form and tablet.
| Claim Nos. |
Claim focus |
Dosage-form limitation |
| 6 |
Composition |
API + pharmaceutically acceptable carrier |
| 7 |
Claim 6 dependency |
Solid dosage form |
| 8 |
Claim 7 dependency |
Tablet |
| 9-10 |
Anhydrate composition |
Solid dosage form, tablet |
| 11-12 |
Hydrate composition |
Solid dosage form |
| 13-14 |
Hemihydrate composition |
Solid dosage form |
| 15-16 |
Solvate composition |
Solid dosage form |
Notably, the tablet limitation appears explicitly at least in the base tablet branch (claim 8) and again for anhydrate (claims 10), while other specific form branches require only solid dosage form in the claim text you provided.
Process claims (combining with carrier)
The process coverage is limited to combining the crystalline freebase with a carrier to make the composition.
| Claim Nos. |
Claim focus |
Process limitation |
| 17 |
Process |
Combine crystalline freebase + pharmaceutically acceptable carrier |
| 18-19 |
Claim 17 dependency |
Solid dosage form, and tablet |
| 20-21 |
Anhydrate process |
Anhydrate crystalline freebase; solid dosage form |
| 22-23 |
Hydrate process |
Hydrate crystalline freebase; solid dosage form |
| 24-25 |
Hemihydrate process |
Hemihydrate crystalline freebase; solid dosage form |
| 26-27 |
Solvate process |
Solvate crystalline freebase; solid dosage form |
Process-prepared composition claims
The patent also includes product-by-process style language limited to the claim-17 combination process.
| Claim Nos. |
Claim focus |
| 28 |
Composition “prepared by the process of claim 17” |
| 29-30 |
Claim 28 dependency |
Solid dosage form; tablet |
How broad are the claims in practice?
The practical coverage splits into two layers: (1) what solid form is protected, and (2) what end-use form is protected.
1) API breadth is high within one compound, lower across solid-state
- The claims are narrow at the scaffold level because the API identity is fully specified (including stereochemistry and substitution pattern).
- Within that single scaffold, the claims are structurally comprehensive across:
- crystalline freebase generally (claim 1)
- anhydrate (claim 2)
- hydrate (claim 3)
- hemihydrate (claim 4)
- solvate (claim 5)
This matters because generic “polymorph” risk often turns on whether the defendant’s material is the claimed freebase crystalline form versus:
- a different polymorph,
- an amorphous form,
- a different solvent inclusion (for solvate),
- or a different hydrate stoichiometry.
2) End-product breadth is moderate and heavily dosage-form oriented
- The composition claims require the crystalline freebase plus carrier and then optionally require solid dosage and tablet.
- Tablet is explicitly claimed for:
- the general composition route (claim 8)
- the anhydrate branch (claim 10)
- the product-by-process composition (claims 30)
- Other crystal-form branches require only “solid dosage form” (claims 12, 14, 16) based on the text you provided.
3) Process claims are “combination” style, not synthesis-process
Claim 17’s process is not a chemical synthesis route; it is a formulation step:
- combining the crystalline freebase with a pharmaceutically acceptable carrier
That framing typically captures:
- formulation stages where the crystalline material is used as an input,
- not the upstream manufacturing of the crystalline freebase itself.
What does claim structure imply about infringement theories?
Given the claim set, the likely infringement paths (for US enforcement) are:
-
Direct infringement of composition/product
- If a product uses the claimed crystalline freebase (including the correct hydrate/anhydrate/solvate form as appropriate), then composition claims (6-16, 28-30) are directly implicated.
-
Direct infringement of tablet specific claims
- If the marketed dosage is a tablet containing the crystalline freebase in the relevant form, claims 8, 10, 30 (and any dependent branches that include tablet by dependency as drafted) align.
-
Process claim exposure in formulation
- Manufacturing the tablet/composition by a step that is legally considered “combining” the crystalline freebase with a carrier aligns with claim 17 and its dependent tablet/solid branches (18-21, 23, 25, 27).
Because the process is generic (no specific unit operations beyond combining), the defense against process claims typically hinges on whether the material used is the claimed crystalline freebase and its specified solid form.
What are the practical “claim-to-operations” mappings?
Below is a mapping from claim scope to common development and manufacturing choices.
| Operational area |
Covered by US 11,680,069 if the product uses… |
Claim hooks |
| API selection |
The specific crystalline freebase identity |
Claim 1 |
| API solid-state control |
Correct form: anhydrate / hydrate / hemihydrate / solvate |
Claims 2-5 |
| Solid formulation |
Composition with carrier in any solid dosage form |
Claims 6-7, 11-16, 28-29 |
| Tablet dosage |
Tablet presentation |
Claims 8, 10, 30 |
| Formulation step |
Combining API + carrier (as a process) |
Claims 17-20, 22, 24, 26 (+ dependents) |
How does this patent typically sit in a crystal-form landscape?
US 11,680,069 appears to be a crystal-form + formulation patent rather than a core compound patent, based on the claim language:
- It does not claim general synthesis chemistry for the active molecule.
- It claims crystalline freebase forms of a narrowly defined compound and their pharmaceutical compositions.
In a typical US patent estate for an H1/H2 class small molecule, crystal-form patents often cluster as:
- compound-specifying claims (earlier),
- then intermediate-form patents (polymorphs/hydrates/solvates),
- then end-product formulation patents (tablets/capsules).
Your claim set fits the “end-product formulation for a specific crystalline freebase form” profile.
US patent landscape: what can be concluded from the claim text provided
A complete US landscape requires bibliographic metadata (assignee, filing/publication numbers, priority date, related family members, and citations). That metadata is not included in the text you provided. Under that constraint, the only defensible “landscape” statements are structural, based solely on the claim scope you pasted.
Non-negotiable scope facts from the claims themselves
- The patent’s enforceable scope is centered on one crystalline freebase compound with fixed stereochemistry and substitutions.
- The enforceable scope is segmented by solid-state form:
- anhydrate
- hydrate
- hemihydrate
- solvate
- The enforceable scope includes:
- compositions (carrier + crystalline freebase)
- tablet embodiments (explicitly in at least claims 8, 10, 30)
- combination formulation processes (claims 17-27)
- product-by-process composition language (claim 28 onward)
What cannot be concluded from your excerpt
- The existence, identity, or relative priority of related US patents in the same family.
- Whether the same assignee has earlier patents on:
- the racemate versus enantiopure material,
- salts versus freebase,
- other polymorphs,
- or the chemical synthesis.
- Whether the patent overlaps or conflicts with third-party crystal-form filings.
- Whether the patent is an unexamined continuation, CIP, division, or family continuation.
- Any expiration dates, term adjustments, or litigation posture.
Key claim takeaways for investors and R&D decision-makers
- If the commercial product uses a crystalline freebase of this exact scaffold, the patent is a direct blocker for formulation containing that API, at least for the solid forms explicitly claimed.
- Solid-state engineering matters: shifting among anhydrate/hydrate/hemihydrate/solvate can be a litigation hinge because the claims are form-dependent.
- Tablet products are the clearest coverage target because tablet is explicitly recited in multiple claim lines (8, 10, 30).
- Manufacturing process defenses likely collapse to API identity and form because the process claims are “combine with carrier,” not tightly bounded chemical steps.
Key Takeaways
- US 11,680,069 claims a specific crystalline freebase of (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide.
- Claim scope is segmented by solid-state form: anhydrate, hydrate, hemihydrate, and solvate.
- It covers pharmaceutical compositions with pharmaceutically acceptable carriers, including solid dosage forms and tablets.
- It includes formulation “combination” processes and product-by-process composition language tied to that combination step.
- The enforceability and infringement risk are dominated by whether the marketed product uses the same crystalline freebase solid form.
FAQs
-
Does US 11,680,069 claim the chemical synthesis of the active pharmaceutical ingredient?
No. The process claims (17-27) are formulation-combination steps with carriers, not upstream synthetic routes.
-
Are salts covered or only the freebase?
The claims explicitly recite crystalline freebase; salt forms are not stated in the claim text you provided.
-
Which solid forms are explicitly protected?
The claim set explicitly covers anhydrate, hydrate, hemihydrate, and solvate (claims 2-5 and the dependent composition/process branches).
-
Do the composition claims require tablets?
Not uniformly. Tablet is explicitly recited for some branches (claims 8, 10, 30), while other branches specify “solid dosage form” without explicitly requiring a tablet.
-
Is there product-by-process coverage?
Yes. Claim 28 ties the composition to preparation by the process of claim 17, followed by solid dosage and tablet limitations in claims 29-30.
References
- US Patent 11,680,069 (claim text as provided by user).
More… ↓
⤷ Start Trial
|
